Ly290024

COS7 and HEK293T cells were purchased from ATCC and maintained in DMEM with 10% fetal bovine serum and 100 units penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO₂. IGF-1, LY290024, Akt1/2 inhibitor and β-actin antibody were from Sigma-Aldrich. Anti-GST, HA, Akt, 14-3-3, pCDK(Y15), p57, cyclin A, cyclin D1, cyclin E, and Hsp90 antibodies were from Santa Cruz Biotechnology. Anti-pAkt substrate, pAkt S473, p21, p27, p53, pRb(S780), Rb, Bax, PARP, and GFP antibodies and recombinant Akt1 were from Cell Signaling Technologies. Anti-pCables1 T44 and T150 antibodies were generated by 21^st Century Biochemicals.

ATRA, rapamycin, LY290024, SB216763 and cycloheximide (CHX) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). U0126, PD184352 and Sorafenib were obtained from LC Laboratories (Woburn, MA, USA). Antibody to Mcl-1, ERK1, Bcl-2, β-actin, and USP9X were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); to PARP was from BD Biosciences (San Diego, CA, USA ); to DR5 was from ProSci, Inc. (Poway, CA, USA); to p-MEK (Ser^217/221), p-ERK (Thr²⁰²/Tyr²⁰⁴), Akt, p-Akt (Ser⁴⁷³), p-mTOR, p70S6K, p-p70S6K (Thr³⁸⁹), p-p70S6K (Thr⁴²¹/Ser⁴²⁴), p-p90RSK (Ser³⁸⁰), p90RSK, p-rpS6 (Ser^235/236), rpS6, GSK-3β, p-GSK-3β (Ser⁹), caspase-8, -9, -3 and Trail were from Cell Signaling Technology, Inc. (Beverly, MA, USA).